XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplemental Guarantor Financial Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Condensed Financial Information Disclosure [Abstract] |
Condensed Consolidating Income and Comprehensive Income Statements | AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Three Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 169.7 |  |  | $ | 37.1 |  |  | $ | (45.9 | ) |  | $ | 160.9 |
Cost of products sold | (0.8 | ) |  | 89.4 |  |  | 23.5 |  |  | (45.9 | ) |  | 66.2 |
Gross Profit | 0.8 |  |  | 80.3 |  |  | 13.6 |  |  | — |  |  | 94.7 |
Research and development | — |  |  | 10.8 |  |  | — |  |  | — |  |  | 10.8 |
Selling and general expenses | 8.7 |  |  | 59.6 |  |  | 11.5 |  |  | — |  |  | 79.8 |
Other income, net | (2.5 | ) |  | (3.0 | ) |  | (3.2 | ) |  | 4.0 |  |  | (4.7 | )
Operating (Loss) Profit | (5.4 | ) |  | 12.9 |  |  | 5.3 |  |  | (4.0 | ) |  | 8.8 |
Interest income | 1.4 |  |  | 0.1 |  |  | 1.8 |  |  | (1.1 | ) |  | 2.2 |
Interest expense | (10.0 | ) |  | (0.9 | ) |  | (0.1 | ) |  | 1.1 |  |  | (9.9 | )
(Loss) Income Before Income Taxes | (14.0 | ) |  | 12.1 |  |  | 7.0 |  |  | (4.0 | ) |  | 1.1 |
Income tax benefit (provision) | 1.0 |  |  | 1.9 |  |  | (2.7 | ) |  | — |  |  | 0.2 |
Equity in earnings of consolidated subsidiaries | 54.8 |  |  | 132.1 |  |  | — |  |  | (186.9 | ) |  | — |
Net Income from Continuing Operations | 41.8 |  |  | 146.1 |  |  | 4.3 |  |  | (190.9 | ) |  | 1.3 |
(Loss) Income from discontinued operations, net of tax | (6.5 | ) |  | (66.8 | ) |  | 107.3 |  |  | — |  |  | 34.0 |
Net Income | 35.3 |  |  | 79.3 |  |  | 111.6 |  |  | (190.9 | ) |  | 35.3 |
Total other comprehensive loss, net of tax | (10.3 | ) |  | (5.7 | ) |  | (8.8 | ) |  | 14.5 |  |  | (10.3 | )
Comprehensive Income | $ | 25.0 |  |  | $ | 73.6 |  |  | $ | 102.8 |  |  | $ | (176.4 | ) |  | $ | 25.0 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Three Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 163.8 |  |  | $ | 80.6 |  |  | $ | (95.3 | ) |  | $ | 149.1 |
Cost of products sold | — |  |  | 96.0 |  |  | 63.9 |  |  | (95.3 | ) |  | 64.6 |
Gross Profit | — |  |  | 67.8 |  |  | 16.7 |  |  | — |  |  | 84.5 |
Research and development | — |  |  | 9.2 |  |  | — |  |  | — |  |  | 9.2 |
Selling and general expenses | 9.7 |  |  | 61.6 |  |  | 9.8 |  |  | — |  |  | 81.1 |
Other expense and (income), net | 0.1 |  |  | 9.2 |  |  | (3.0 | ) |  | — |  |  | 6.3 |
Operating (Loss) Income | (9.8 | ) |  | (12.2 | ) |  | 9.9 |  |  | — |  |  | (12.1 | )
Interest income | 0.2 |  |  | — |  |  | 1.1 |  |  | (0.8 | ) |  | 0.5 |
Interest expense | (8.0 | ) |  | (0.5 | ) |  | (0.1 | ) |  | 0.8 |  |  | (7.8 | )
(Loss) Income Before Income Taxes | (17.6 | ) |  | (12.7 | ) |  | 10.9 |  |  | — |  |  | (19.4 | )
Income tax benefit | 1.3 |  |  | 5.3 |  |  | 1.4 |  |  | — |  |  | 8.0 |
Equity in earnings of consolidated subsidiaries | 28.2 |  |  | 9.9 |  |  | — |  |  | (38.1 | ) |  | — |
Net Income (Loss) from Continuing Operations | 11.9 |  |  | 2.5 |  |  | 12.3 |  |  | (38.1 | ) |  | (11.4 | )
Income from discontinued operations, net of tax | 5.2 |  |  | 19.2 |  |  | 4.1 |  |  | — |  |  | 28.5 |
Net Income | 17.1 |  |  | 21.7 |  |  | 16.4 |  |  | (38.1 | ) |  | 17.1 |
Total other comprehensive income, net of tax | 5.1 |  |  | 3.4 |  |  | 5.2 |  |  | (8.6 | ) |  | 5.1 |
Comprehensive Income | $ | 22.2 |  |  | $ | 25.1 |  |  | $ | 21.6 |  |  | $ | (46.7 | ) |  | $ | 22.2 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Six Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 343.0 |  |  | $ | 112.0 |  |  | $ | (137.7 | ) |  | $ | 317.3 |
Cost of products sold | (0.8 | ) |  | 173.9 |  |  | 96.1 |  |  | (137.7 | ) |  | 131.5 |
Gross Profit | 0.8 |  |  | 169.1 |  |  | 15.9 |  |  | — |  |  | 185.8 |
Research and development | — |  |  | 20.7 |  |  | — |  |  | — |  |  | 20.7 |
Selling and general expenses | 20.6 |  |  | 122.0 |  |  | 23.6 |  |  | — |  |  | 166.2 |
Other (income) and expense, net | (2.2 | ) |  | 1.2 |  |  | (5.9 | ) |  | 4.0 |  |  | (2.9 | )
Operating (Loss) Income | (17.6 | ) |  | 25.2 |  |  | (1.8 | ) |  | (4.0 | ) |  | 1.8 |
Interest income | 1.8 |  |  | 0.1 |  |  | 3.2 |  |  | (1.9 | ) |  | 3.2 |
Interest expense | (18.9 | ) |  | (1.6 | ) |  | (0.1 | ) |  | 1.9 |  |  | (18.7 | )
(Loss) Income Before Income Taxes | (34.7 | ) |  | 23.7 |  |  | 1.3 |  |  | (4.0 | ) |  | (13.7 | )
Income tax benefit (provision) | 8.9 |  |  | (1.3 | ) |  | (3.9 | ) |  | — |  |  | 3.7 |
Equity in earnings of consolidated subsidiaries | 87.8 |  |  | 140.6 |  |  | — |  |  | (228.4 | ) |  | — |
Net Income (Loss) from Continuing Operations | 62.0 |  |  | 163.0 |  |  | (2.6 | ) |  | (232.4 | ) |  | (10.0 | )
(Loss) Income from discontinued operations, net of tax | (6.5 | ) |  | (49.9 | ) |  | 121.9 |  |  | — |  |  | 65.5 |
Net Income | 55.5 |  |  | 113.1 |  |  | 119.3 |  |  | (232.4 | ) |  | 55.5 |
Total other comprehensive (loss) income, net of tax | (0.8 | ) |  | 2.8 |  |  | (0.7 | ) |  | (2.1 | ) |  | (0.8 | )
Comprehensive Income | $ | 54.7 |  |  | $ | 115.9 |  |  | $ | 118.6 |  |  | $ | (234.5 | ) |  | $ | 54.7 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Six Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 325.9 |  |  | $ | 145.2 |  |  | $ | (176.3 | ) |  | $ | 294.8 |
Cost of products sold | — |  |  | 180.9 |  |  | 124.2 |  |  | (176.3 | ) |  | 128.8 |
Gross Profit | — |  |  | 145.0 |  |  | 21.0 |  |  | — |  |  | 166.0 |
Research and development | — |  |  | 16.5 |  |  | — |  |  | — |  |  | 16.5 |
Selling and general expenses | 19.7 |  |  | 125.6 |  |  | 20.6 |  |  | — |  |  | 165.9 |
Other expense and (income), net | 0.3 |  |  | 18.8 |  |  | (5.8 | ) |  | — |  |  | 13.3 |
Operating (Loss) Profit | (20.0 | ) |  | (15.9 | ) |  | 6.2 |  |  | — |  |  | (29.7 | )
Interest income | 0.4 |  |  | — |  |  | 2.1 |  |  | (1.6 | ) |  | 0.9 |
Interest expense | (15.8 | ) |  | (1.1 | ) |  | (0.1 | ) |  | 1.6 |  |  | (15.4 | )
(Loss) Income Before Income Taxes | (35.4 | ) |  | (17.0 | ) |  | 8.2 |  |  | — |  |  | (44.2 | )
Income tax benefit | 2.5 |  |  | 14.5 |  |  | 0.9 |  |  | — |  |  | 17.9 |
Equity in earnings of consolidated subsidiaries | 52.1 |  |  | 13.0 |  |  | — |  |  | (65.1 | ) |  | — |
Net Income (Loss) from Continuing Operations | 19.2 |  |  | 10.5 |  |  | 9.1 |  |  | (65.1 | ) |  | (26.3 | )
Income from discontinued operations, net of tax | 10.7 |  |  | 35.7 |  |  | 9.8 |  |  | — |  |  | 56.2 |
Net Income | 29.9 |  |  | 46.2 |  |  | 18.9 |  |  | (65.1 | ) |  | 29.9 |
Total other comprehensive income, net of tax | 15.8 |  |  | 11.9 |  |  | 14.9 |  |  | (26.8 | ) |  | 15.8 |
Comprehensive Income | $ | 45.7 |  |  | $ | 58.1 |  |  | $ | 33.8 |  |  | $ | (91.9 | ) |  | $ | 45.7 |
Condensed Consolidating Balance Sheet | AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 109.9 |  |  | $ | 77.7 |  |  | $ | 292.0 |  |  | $ | — |  |  | $ | 479.6 |
Restricted cash | 51.5 |  |  | — |  |  | — |  |  | — |  |  | 51.5 |
Accounts receivable, net of allowances | 2.2 |  |  | 1,074.7 |  |  | 208.7 |  |  | (1,096.4 | ) |  | 189.2 |
Inventories | — |  |  | 92.9 |  |  | 14.9 |  |  | — |  |  | 107.8 |
Prepaid expenses and other current assets | 11.9 |  |  | 15.8 |  |  | 29.2 |  |  | (8.5 | ) |  | 48.4 |
Total Current Assets | 175.5 |  |  | 1,261.1 |  |  | 544.8 |  |  | (1,104.9 | ) |  | 876.5 |
Property, Plant and Equipment, net | — |  |  | 104.5 |  |  | 19.0 |  |  | — |  |  | 123.5 |
Investment in Consolidated Subsidiaries | 2,303.7 |  |  | 475.7 |  |  | — |  |  | (2,779.4 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 25.7 |  |  | — |  |  | 763.8 |
Other Intangible Assets, net | — |  |  | 130.6 |  |  | 8.9 |  |  | — |  |  | 139.5 |
Other Assets | 0.1 |  |  | 9.6 |  |  | 4.4 |  |  | — |  |  | 14.1 |
TOTAL ASSETS | $ | 2,479.3 |  |  | $ | 2,719.6 |  |  | $ | 602.8 |  |  | $ | (3,884.3 | ) |  | $ | 1,917.4 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Trade accounts payable | $ | 930.6 |  |  | $ | 286.1 |  |  | $ | 46.7 |  |  | $ | (1,086.5 | ) |  | $ | 176.9 |
Accrued expenses | 6.4 |  |  | 160.0 |  |  | 27.9 |  |  | (18.4 | ) |  | 175.9 |
Total Current Liabilities | 937.0 |  |  | 446.1 |  |  | 74.6 |  |  | (1,104.9 | ) |  | 352.8 |
Long-Term Debt | 247.4 |  |  | — |  |  | — |  |  | — |  |  | 247.4 |
Other Long-Term Liabilities | 8.3 |  |  | 18.8 |  |  | 3.5 |  |  | — |  |  | 30.6 |
Total Liabilities | 1,192.7 |  |  | 464.9 |  |  | 78.1 |  |  | (1,104.9 | ) |  | 630.8 |
Total Equity | 1,286.6 |  |  | 2,254.7 |  |  | 524.7 |  |  | (2,779.4 | ) |  | 1,286.6 |
TOTAL LIABILITIES AND EQUITY | $ | 2,479.3 |  |  | $ | 2,719.6 |  |  | $ | 602.8 |  |  | $ | (3,884.3 | ) |  | $ | 1,917.4 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
Accounts receivable, net of allowances | 1.1 |  |  | 623.0 |  |  | 266.3 |  |  | (687.4 | ) |  | 203.0 |
Inventories | — |  |  | 76.0 |  |  | 15.1 |  |  | — |  |  | 91.1 |
Prepaid expenses and other current assets | 0.6 |  |  | 11.7 |  |  | 2.1 |  |  | — |  |  | 14.4 |
Assets held for sale | 0.3 |  |  | 546.7 |  |  | 85.5 |  |  | — |  |  | 632.5 |
Total Current Assets | 116.5 |  |  | 1,273.4 |  |  | 458.2 |  |  | (687.4 | ) |  | 1,160.7 |
Property, Plant and Equipment, net | — |  |  | 92.9 |  |  | 17.0 |  |  | — |  |  | 109.9 |
Investment in Consolidated Subsidiaries | 2,154.3 |  |  | 403.2 |  |  | — |  |  | (2,557.5 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 26.6 |  |  | — |  |  | 764.7 |
Other Intangible Assets, net | — |  |  | 139.5 |  |  | 9.4 |  |  | — |  |  | 148.9 |
Other Assets | 0.3 |  |  | 6.0 |  |  | 5.4 |  |  | — |  |  | 11.7 |
TOTAL ASSETS | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Current portion of long-term debt | $ | 39.8 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 39.8 |
Trade accounts payable | 454.0 |  |  | 347.0 |  |  | 49.8 |  |  | (679.6 | ) |  | 171.2 |
Accrued expenses | 11.6 |  |  | 113.9 |  |  | 27.4 |  |  | (8.0 | ) |  | 144.9 |
Liabilities held for sale | — |  |  | 7.8 |  |  | 26.1 |  |  | — |  |  | 33.9 |
Total Current Liabilities | 505.4 |  |  | 468.7 |  |  | 103.3 |  |  | (687.6 | ) |  | 389.8 |
Long-Term Debt | 541.1 |  |  | — |  |  | — |  |  | — |  |  | 541.1 |
Other Long-Term Liabilities | 9.2 |  |  | 36.1 |  |  | 4.3 |  |  | — |  |  | 49.6 |
Total Liabilities | 1,055.7 |  |  | 504.8 |  |  | 107.6 |  |  | (687.6 | ) |  | 980.5 |
Total Equity | 1,215.4 |  |  | 2,148.3 |  |  | 409.0 |  |  | (2,557.3 | ) |  | 1,215.4 |
TOTAL LIABILITIES AND EQUITY | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
Condensed Consolidating Statements of Cash Flows | AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Six Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (114.2 | ) |  | $ | 31.3 |  |  | $ | 12.5 |  |  | $ | — |  |  | $ | (70.4 | )
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (15.0 | ) |  | (5.7 | ) |  | — |  |  | (20.7 | )
Proceeds from the Divestiture | 521.6 |  |  | 9.0 |  |  | 203.9 |  |  | — |  |  | 734.5 |
Intercompany contributions | — |  |  | 36.3 |  |  | — |  |  | (36.3 | ) |  | — |
Cash Provided by Investing Activities | 521.6 |  |  | 30.3 |  |  | 198.2 |  |  | (36.3 | ) |  | 713.8 |
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | (32.3 | ) |  | — |  |  | (4.0 | ) |  | 36.3 |  |  | — |
Debt repayments | (339.0 | ) |  | — |  |  | — |  |  | — |  |  | (339.0 | )
Purchase of treasury stock | (0.6 | ) |  | — |  |  | — |  |  | — |  |  | (0.6 | )
Proceeds from the exercise of stock options | 11.4 |  |  | — |  |  | — |  |  | — |  |  | 11.4 |
Cash Used in Financing Activities | (360.5 | ) |  | — |  |  | (4.0 | ) |  | 36.3 |  |  | (328.2 | )
Effect of Exchange Rate on Cash, Cash Equivalents and Restricted Cash | — |  |  | 0.1 |  |  | (3.9 | ) |  | — |  |  | (3.8 | )
Increase in Cash, Cash Equivalents and Restricted Cash | 46.9 |  |  | 61.7 |  |  | 202.8 |  |  | — |  |  | 311.4 |
Cash and Cash Equivalents, Beginning of Period | 114.5 |  |  | 16.0 |  |  | 89.2 |  |  | — |  |  | 219.7 |
Cash, Cash Equivalents and Restricted Cash, End of Period | $ | 161.4 |  |  | $ | 77.7 |  |  | $ | 292.0 |  |  | $ | — |  |  | $ | 531.1 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Six Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (21.1 | ) |  | $ | 73.7 |  |  | $ | 4.1 |  |  | $ | — |  |  | $ | 56.7 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (13.0 | ) |  | (3.6 | ) |  | — |  |  | (16.6 | )
Proceeds from property dispositions | — |  |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Intercompany contributions | — |  |  | (55.1 | ) |  | — |  |  | 55.1 |  |  | — |
Cash Used in Investing Activities | — |  |  | (68.0 | ) |  | (3.6 | ) |  | 55.1 |  |  | (16.5 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 57.8 |  |  | — |  |  | (2.7 | ) |  | (55.1 | ) |  | — |
Purchase of treasury stock | (2.0 | ) |  | — |  |  | — |  |  | — |  |  | (2.0 | )
Proceeds from the exercise of stock options | 0.8 |  |  | — |  |  | — |  |  | — |  |  | 0.8 |
Cash Provided by (Used in) Financing Activities | 56.6 |  |  | — |  |  | (2.7 | ) |  | (55.1 | ) |  | (1.2 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | 0.3 |  |  | 1.8 |  |  | — |  |  | 2.1 |
Increase (Decrease) in Cash and Cash Equivalents | 35.5 |  |  | 6.0 |  |  | (0.4 | ) |  | — |  |  | 41.1 |
Cash and Cash Equivalents, Beginning of Period | 54.2 |  |  | 9.5 |  |  | 50.0 |  |  | — |  |  | 113.7 |
Cash and Cash Equivalents, End of Period | $ | 89.7 |  |  | $ | 15.5 |  |  | $ | 49.6 |  |  | $ | — |  |  | $ | 154.8 |

X
- References No definition available. + Details
Name: | srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration